CATAPULT SPORTS LIMITED (CAT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CAT

CAT - CATAPULT SPORTS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Technology Hardware & Equipment
Debt/EBITDA: 0.55
Index: ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Catapult Group develops and sells wearable sensors to monitor and analyse athletic performance, including fitness and skill levels, injury risks and rehabilitation assistance. It listed on the ASX in 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.53

11 Feb
2026

0.030

OPEN

$3.50

0.86%

HIGH

$3.54

1,082,124

LOW

$3.38

TARGET
$5.856

-0.63 change from previous day

 65.9% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
CAT: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 10.3 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 201920212022202320242025
EPS Basic xxxxxxxxxxxxxxx-5.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx178.7 M
Book Value Per Share xxxxxxxxxxxxxxx49.9
Net Operating Cash Flow xxxxxxxxxxxxxxx56.1 M
Net Profit Margin xxxxxxxxxxxxxxx-7.51 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-10.64 %
Return on Invested Capital xxxxxxxxxxxxxxx-9.17 %
Return on Assets xxxxxxxxxxxxxxx-5.18 %
Return on Equity xxxxxxxxxxxxxxx-10.64 %
Return on Total Capital xxxxxxxxxxxxxxx-8.47 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx36.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx13 M
Total Debt xxxxxxxxxxxxxxx16 M
Goodwill - Gross xxxxxxxxxxxxxxx82 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx17 M
Price To Book Value xxxxxxxxxxxxxxx6.93

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920212022202320242025
Capex xxxxxxxxxxxxxxx45.8 M
Capex % of Sales xxxxxxxxxxxxxxx25.62 %
Cost of Goods Sold xxxxxxxxxxxxxxx162 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx29 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxxxxxxxxx xx xxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

27/11/2025

1

Reinstate Coverage with Buy

$6.25

77.05%

Morgans re-instates coverage of Catapult Sports with a Buy rating and $6.25 target. The company has expanded its service offering and opened up new key verticals.

The broker forecasts strong top-line growth, estimating a 20% compound growth rate over three years and reaching US$180m by FY28.

Strong positive momentum has occurred across key performance metrics including recurring revenue, incremental profit margins and the number of professional teams taking up multiple products.

Free cash flow has now been achieved and, with no debt on the balance sheet, should provide the necessary options for growth, the broker adds.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -7.21 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.07 cents.

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

20/11/2025

1

Buy

$8.00

126.63%

Catapult Sports announced 1H26 numbers that were a slight 'beat' on largely pre-reported results.

Canaccord Genuity notes revenue rose 16% y/y in constant currency, with subscription revenue growth of 20% y/y which aligns with its 20% growth in annual contract value. Gross profit lifted 17% y/y with a 79% gross margin.

Management retained the positive outlook for FY26, flagging "strong annual contract growth and low churn".

The analyst highlights the rotation out of growth stocks over the last month and views the sell down in the share price at over -35% as overdone.

Buy rating retained with an unchanged target of $8.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.46 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 3.99 cents.
Access Extra Coverage Research History >

CAT STOCK CHART

FNArena News on CAT

1
Rudi’s View: February Favourites & Avoids

Jan 29 2026 - Rudi's View
2
Rudi’s View: Best Buys & Favourites For 2026

Dec 24 2025 - Rudi's View
3
Rudi’s View: Copper, Aluminium & Technology (!)

Dec 11 2025 - Rudi's View
4
Rudi’s View: Momentum Favours Resources

Dec 04 2025 - Rudi's View
5
Rudi’s View: Un-Bubbling The AI Bubble Talk

Nov 27 2025 - Rudi's View

Latest Medical Equipment & Devices News

1
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
2
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
3
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
4
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
5
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
6
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
7
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
8
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
9
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
10
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia